These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 19464064

  • 1. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
    Berger RM, Beghetti M, Galiè N, Gatzoulis MA, Granton J, Lauer A, Chiossi E, Landzberg M.
    Int J Cardiol; 2010 Oct 29; 144(3):373-8. PubMed ID: 19464064
    [Abstract] [Full Text] [Related]

  • 2. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.
    Circulation; 2006 Jul 04; 114(1):48-54. PubMed ID: 16801459
    [Abstract] [Full Text] [Related]

  • 3. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.
    Int J Cardiol; 2012 Mar 22; 155(3):378-82. PubMed ID: 21081251
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study.
    Garg N, Tripathy N, Sinha N.
    Cardiol Young; 2011 Dec 22; 21(6):631-8. PubMed ID: 21729508
    [Abstract] [Full Text] [Related]

  • 5. Repair of ventricular septal defect with Eisenmenger syndrome after bosentan treatment.
    Hu L, Tan LH, Ye J.
    J Card Surg; 2014 May 22; 29(3):401-2. PubMed ID: 24612361
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
    Zeng WJ, Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Gu Q, Zhao ZH, Li JJ, He JG, Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Group.
    Clin Cardiol; 2011 Aug 22; 34(8):513-8. PubMed ID: 21678455
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J, Papadakis K, Pulido T, Galiè N, MAESTRO Study Investigators.
    Circulation; 2019 Jan 02; 139(1):51-63. PubMed ID: 30586694
    [Abstract] [Full Text] [Related]

  • 8. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E, Sy R, Keogh AM, Kermeen F, Macdonald PS, Hayward CS, McNeil KD, Celermajer DS.
    Cardiol Young; 2006 Jun 02; 16(3):268-74. PubMed ID: 16725066
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, Berger RM.
    Am Heart J; 2007 Oct 02; 154(4):776-82. PubMed ID: 17893008
    [Abstract] [Full Text] [Related]

  • 12. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ.
    Lancet; 2001 Oct 06; 358(9288):1119-23. PubMed ID: 11597664
    [Abstract] [Full Text] [Related]

  • 13. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group.
    J Am Coll Cardiol; 2008 Dec 16; 52(25):2127-34. PubMed ID: 19095129
    [Abstract] [Full Text] [Related]

  • 14. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.
    Engelfriet PM, Duffels MG, Möller T, Boersma E, Tijssen JG, Thaulow E, Gatzoulis MA, Mulder BJ.
    Heart; 2007 Jun 16; 93(6):682-7. PubMed ID: 17164490
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Associated atrial septal defects increase perioperative morbidity after ventricular septal defect repair in infancy.
    Knott-Craig CJ, Elkins RC, Ramakrishnan K, Hartnett DA, Lane MM, Overholt ED, Ward KE, Razook JR.
    Ann Thorac Surg; 1995 Mar 16; 59(3):573-8. PubMed ID: 7887692
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I, Otero-González I, Blanco-Aparicio M, Ferrer-Barba A, Medrano-López C.
    Rev Esp Cardiol; 2007 Apr 16; 60(4):366-72. PubMed ID: 17521545
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.